Engineered T Cell Therapy for Gynecologic Malignancies: Challenges and Opportunities

Yifan Xu; Jin Jiang; Yutong Wang; Wei Wang; Haokun Li; Wenyu Lai; Zhipeng Zhou; Wei Zhu; Zheng Xiang; Zhiming Wang; Zhe Zhu; Lingfeng Yu; Xiaolan Huang; Hua Zheng; Sha Wu

doi:10.3389/fimmu.2021.725330

Engineered T Cell Therapy for Gynecologic Malignancies: Challenges and Opportunities

Front Immunol. 2021 Jul 27:12:725330. doi: 10.3389/fimmu.2021.725330. eCollection 2021.

Authors

Yifan Xu^{1

2}, Jin Jiang³, Yutong Wang^{1

2}, Wei Wang⁴, Haokun Li^{1

2}, Wenyu Lai^{1

2}, Zhipeng Zhou^{1

2}, Wei Zhu⁵, Zheng Xiang⁶, Zhiming Wang⁷, Zhe Zhu⁸, Lingfeng Yu⁹, Xiaolan Huang⁴, Hua Zheng¹⁰, Sha Wu^{2

11}

Affiliations

¹ Microbiome Medicine Center, Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
² Department of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.
³ Guangzhou Blood Center, Department of Blood Source Management, Guangzhou, China.
⁴ Department of Obstetrics and Gynecology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
⁵ Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
⁶ Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.
⁷ State Key Laboratory of Esophageal Cancer Prevention & Treatment, Sino-British Research Center for Molecular Oncology, National Center for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China.
⁸ Huikezhe Biological Tech. Beijing, R&D Department, Beijing, China.
⁹ School of Basic Medicine Science, Tianjin Medical University, Tianjin, China.
¹⁰ Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
¹¹ National Demonstration Center for Experimental Education of Basic Medical Sciences, Southern Medical University, Guangzhou, China.

Abstract

Gynecologic malignancies, mainly including ovarian cancer, cervical cancer and endometrial cancer, are leading causes of death among women worldwide with high incidence and mortality rate. Recently, adoptive T cell therapy (ACT) using engineered T cells redirected by genes which encode for tumor-specific T cell receptors (TCRs) or chimeric antigen receptors (CARs) has demonstrated a delightful potency in B cell lymphoma treatment. Researches impelling ACT to be applied in treating solid tumors like gynecologic tumors are ongoing. This review summarizes the preclinical research and clinical application of engineered T cells therapy for gynecologic cancer in order to arouse new thoughts for remedies of this disease.

Keywords: CAR-T; TCR-T; adoptive T cell therapy; engineered T cells; gynecologic malignancies; immunotherapy.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Cell- and Tissue-Based Therapy / methods*
Female
Genital Neoplasms, Female / immunology
Genital Neoplasms, Female / pathology
Genital Neoplasms, Female / therapy*
Humans
Immunotherapy, Adoptive / methods*
Receptors, Chimeric Antigen / immunology*
T-Lymphocytes / immunology
T-Lymphocytes / transplantation*

Substances

Receptors, Chimeric Antigen